News

Novo Nordisk AS (NVO) Q1 2025 Earnings Call Highlights: Robust Growth Amid Challenges
Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its ...
The Economist14h
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% ...
Is Novo Nordisk A/S (NVO) The Best Stock to Buy and Hold For 10 Years?
We recently compiled a list of the 12 Best Stocks to Buy and Hold For 10 Years. In this article, we are going to take a look ...
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
The Zacks Analyst Blog Highlights Novo Nordisk, Honeywell International and American Tower
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...